Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

Employees - 29, CEO - Carl Spana, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -43.26, Piotroski Score(max is 10): 4, Working Capital: $10249248, Total Assets: $13225337, Retained Earnings: $-463093213, EBIT: -6241857, Total Liabilities: $2633459, Revenue: $12884261

AryaFin Target Price - $4.45 - Current Price $ - Analyst Target Price $